Integra LifeSciences Swings to $515M Loss on Goodwill Impairment

TL;DR

**IART's massive goodwill impairment and increased debt are flashing red flags; steer clear until they prove they can integrate acquisitions profitably.**

AI Summary

Integra LifeSciences Holdings Corp (IART) reported a significant net loss of $514.77 million for the nine months ended September 30, 2025, a substantial increase from the $26.38 million net loss in the prior year, primarily driven by a $511.37 million goodwill impairment charge. Total revenue, net, increased to $1.20 billion for the nine months ended September 30, 2025, up from $1.17 billion in the same period of 2024, representing a 2.8% growth. For the three months ended September 30, 2025, revenue grew to $402.06 million from $380.83 million in 2024. Operating income for the quarter was $11.76 million, a turnaround from an $8.15 million operating loss in the prior year's quarter, but the nine-month period saw an operating loss of $516.41 million due to the impairment. The company's cash and cash equivalents decreased from $246.38 million at December 31, 2024, to $232.19 million at September 30, 2025. Long-term borrowings under the senior credit facility increased significantly from $1.09 billion to $1.71 billion, while convertible securities decreased from $573.17 million to zero, indicating a repayment. The company also incurred $8.13 million in employee termination costs related to restructuring activities during the nine months ended September 30, 2025.

Why It Matters

This substantial net loss, primarily due to a goodwill impairment charge, signals potential overvaluation of past acquisitions and could erode investor confidence in IART's asset management and future profitability. The increased long-term debt, despite convertible debt repayment, raises concerns about the company's leverage and ability to fund future growth or manage interest expenses in a rising rate environment. For employees, the $8.13 million in restructuring-related termination costs indicates ongoing operational adjustments, potentially impacting morale and job security. Competitively, this financial performance could weaken IART's position against rivals like Medtronic and Johnson & Johnson, who are also active in the medical device space, by limiting investment in R&D or market expansion.

Risk Assessment

Risk Level: high — The company reported a net loss of $514.77 million for the nine months ended September 30, 2025, primarily due to a $511.37 million goodwill impairment charge. This significant non-cash charge indicates a substantial reduction in the value of prior acquisitions, suggesting potential overpayment or underperformance. Additionally, long-term borrowings under the senior credit facility increased by $620.93 million, from $1.09 billion at December 31, 2024, to $1.71 billion at September 30, 2025, increasing financial leverage.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to IART given the massive goodwill impairment and increased debt. A thorough review of the company's acquisition strategy and future cash flow projections is warranted before making any new investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

$1.20B

operating Margin

-43.0%

total Assets

$3.65B

total Debt

$1.75B

net Income

$ -514.77M

eps

$ -6.72

gross Margin

N/A

cash Position

$232.19M

revenue Growth

+2.8%

Revenue Breakdown

Key Numbers

• $514.77M — Net Loss (For the nine months ended September 30, 2025, a significant increase from $26.38M in 2024.)
• $511.37M — Goodwill Impairment Charge (Primary driver of the net loss for the nine months ended September 30, 2025.)
• $1.20B — Total Revenue, Net (For the nine months ended September 30, 2025, up from $1.17B in 2024.)
• $1.71B — Long-term Borrowings (Senior Credit Facility) (As of September 30, 2025, a substantial increase from $1.09B at December 31, 2024.)
• $573.17M — Convertible Securities (Reduced from $573.17M at December 31, 2024, to zero at September 30, 2025, indicating repayment.)
• $8.13M — Employee Termination Costs (Payments) (Incurred for restructuring activities during the nine months ended September 30, 2025.)
• $232.19M — Cash and Cash Equivalents (As of September 30, 2025, a decrease from $246.38M at December 31, 2024.)
• $402.06M — Total Revenue, Net (Q3) (For the three months ended September 30, 2025, up from $380.83M in 2024.)

Key Players & Entities

• INTEGRA LIFESCIENCES HOLDINGS CORP (company) — Registrant
• Medtronic plc (company) — Seller of Durepair product rights
• Ethicon, Inc. (company) — Seller of Acclarent, Inc.
• Johnson & Johnson (company) — Parent company of Ethicon, Inc.
• Durepair Regeneration Matrix (product) — Acquired product rights
• Acclarent, Inc. (company) — Acquired company
• $514,770 (dollar_amount) — Net loss for nine months ended September 30, 2025
• $511,365 (dollar_amount) — Goodwill impairment charge for nine months ended September 30, 2025
• $1,708,851 (dollar_amount) — Long-term borrowings under senior credit facility as of September 30, 2025
• $8,129 (dollar_amount) — Payments and other adjustments for employee termination benefits for nine months ended September 30, 2025

FAQ

Risk Factors

• Significant Goodwill Impairment [high — financial]: The company recorded a substantial goodwill impairment charge of $511.37 million for the nine months ended September 30, 2025. This charge significantly impacted net income, leading to a net loss of $514.77 million for the period, compared to a $26.38 million net loss in the prior year.
• Increased Debt Levels [high — financial]: Long-term borrowings under the senior credit facility increased significantly from $1.09 billion at December 31, 2024, to $1.71 billion as of September 30, 2025. This substantial increase in leverage could heighten financial risk.
• Decreased Cash Position [medium — financial]: Cash and cash equivalents decreased from $246.38 million at the end of 2024 to $232.19 million as of September 30, 2025. This reduction, coupled with increased debt, may limit financial flexibility.
• Restructuring Costs [medium — operational]: The company incurred $8.13 million in employee termination costs related to restructuring activities during the nine months ended September 30, 2025. While aimed at future efficiency, these costs represent an immediate financial burden.
• Repayment of Convertible Securities [medium — financial]: Convertible securities decreased from $573.17 million to zero, indicating a significant repayment. While this reduces a liability, it likely required substantial cash outflow or refinancing.
• Operating Loss Despite Revenue Growth [high — financial]: Despite a 2.8% increase in net revenue for the nine months ended September 30, 2025, the company reported an operating loss of $516.41 million, heavily influenced by the goodwill impairment. The quarterly operating income of $11.76 million shows a turnaround from the prior year's quarter loss of $8.15 million, but the nine-month trend remains concerning.

Industry Context

Integra LifeSciences operates in the highly competitive medical technology sector, focusing on surgical instruments, neurosurgery, and regenerative technologies. The industry is characterized by rapid innovation, stringent regulatory oversight (FDA, etc.), and consolidation. Companies like IART face pressure to demonstrate clinical efficacy and cost-effectiveness to gain market share against larger, well-established players and smaller, specialized firms.

Regulatory Implications

As a medical device company, IART is subject to rigorous regulatory scrutiny from bodies like the FDA. Changes in healthcare policy, reimbursement rates, and compliance requirements for product safety and efficacy can significantly impact revenue and operational costs. The company must maintain robust quality management systems and navigate complex approval processes for new and existing products.

What Investors Should Do

1. Monitor debt levels and cash flow closely.
2. Analyze the sustainability of revenue growth.
3. Evaluate the impact of restructuring and future growth initiatives.
4. Assess the impact of the goodwill impairment on future performance.

Key Dates

• 2025-09-30: Nine Months Ended — Reported a net loss of $514.77M, driven by a $511.37M goodwill impairment, and total revenue of $1.20B.
• 2025-09-30: Quarter Ended — Reported revenue of $402.06M and operating income of $11.76M, a turnaround from the prior year's quarter operating loss.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents stood at $232.19M, while long-term borrowings increased to $1.71B.
• 2024-12-31: Prior Year End — Cash and cash equivalents were $246.38M, and long-term borrowings were $1.09B. Convertible securities were $573.17M.

Glossary

Goodwill impairment charge

A non-cash expense recognized when the carrying value of goodwill on a company's balance sheet exceeds its fair value, indicating a loss in value of the acquired business. (This was the primary driver of the significant net loss for IART in the nine-month period, totaling $511.37 million.)

Senior credit facility

A type of loan agreement, typically provided by a syndicate of banks, that has priority over other unsecured or subordinated debt in the event of bankruptcy or liquidation. (IART's long-term borrowings under this facility increased substantially, indicating increased financial leverage.)

Convertible securities

Financial instruments that can be converted into a predetermined amount of the issuer's equity at certain times during their life. (IART's convertible securities balance decreased to zero, signifying a repayment or conversion, impacting its debt and equity structure.)

Operating income (loss)

A measure of a company's profit after deducting operating expenses from its revenue, excluding interest and taxes. (While the company showed a quarterly operating profit, the nine-month period resulted in a significant operating loss due to the impairment charge.)

Net loss per share

The portion of a company's profit or loss allocated to each outstanding share of common stock. (Reflects the substantial loss incurred by IART, with a basic and diluted loss per share of $6.72 for the nine-month period.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Integra LifeSciences reported a substantial increase in net loss, from $26.38 million to $514.77 million, primarily due to a $511.37 million goodwill impairment charge. Total revenue saw modest growth, increasing by 2.8% to $1.20 billion. While the company managed to turn an operating loss into an operating profit on a quarterly basis, the nine-month operating loss widened significantly. Debt has increased substantially, with long-term borrowings rising from $1.09 billion to $1.71 billion, while convertible securities were fully repaid.

Key Financial Figures

• $0.01 — hares of the registrant's Common Stock, $0.01 par value, outstanding as of October 29

Filing Documents

• iart-20250930.htm (10-Q) — 1956KB
• iart-20250930xexx311.htm (EX-31.1) — 10KB
• iart-20250930xexx312.htm (EX-31.2) — 10KB
• iart-20250930xexx321.htm (EX-32.1) — 5KB
• iart-20250930xexx322.htm (EX-32.2) — 5KB
• 0000917520-25-000096.txt ( ) — 11704KB
• iart-20250930.xsd (EX-101.SCH) — 71KB
• iart-20250930_cal.xml (EX-101.CAL) — 96KB
• iart-20250930_def.xml (EX-101.DEF) — 421KB
• iart-20250930_lab.xml (EX-101.LAB) — 863KB
• iart-20250930_pre.xml (EX-101.PRE) — 651KB
• iart-20250930_htm.xml (XML) — 2238KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended Septemb er 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Changes in Shareholders' Equity for the Nine Months Ended Septemb er 30, 2025 and 2024 (Unaudited) 6 Notes to Unaudited Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 38

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 52

Controls and Procedures

Item 4. Controls and Procedures 53

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 53

Risk Factors

Item 1A. Risk Factors 53

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 53

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 54

Other Information

Item 5. Other Information 54

Exhibits

Item 6. Exhibits 54

SIGNATURES

SIGNATURES 56 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (Dollars in thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Total revenue, net $ 402,062 $ 380,834 $ 1,200,320 $ 1,167,881 Costs and expenses: Cost of goods sold 195,071 180,596 589,565 534,892 Research and development 22,456 27,435 74,181 84,167 Selling, general and administrative 169,046 177,193 530,433 538,463 Intangible asset amortization 3,728 3,760 11,186 17,575 Goodwill impairment charge — — 511,365 — Total costs and expenses 390,301 388,984 1,716,730 1,175,097 Operating income (loss) 11,761 ( 8,150 ) ( 516,410 ) ( 7,216 ) Interest income 4,982 5,049 14,112 15,147 Interest expense ( 22,725 ) ( 19,373 ) ( 62,582 ) ( 51,648 ) Other (expense) income, net ( 842 ) 2,112 ( 2,932 ) 2,939 Loss before income taxes ( 6,824 ) ( 20,362 ) ( 567,812 ) ( 40,778 ) Benefit for income taxes ( 1,420 ) ( 9,667 ) ( 53,042 ) ( 14,399 ) Net loss $ ( 5,404 ) $ ( 10,695 ) $ ( 514,770 ) $ ( 26,379 ) Net loss per share Basic and diluted $ ( 0.07 ) $ ( 0.14 ) $ ( 6.72 ) $ ( 0.34 ) Weighted average common shares outstanding (See Note 13): Basic and diluted 76,753 76,448 76,637 77,196 Comprehensive loss (See Note 14) ( 6,472 ) ( 16,823 ) ( 519,174 ) $ ( 36,126 ) The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Dollars in thousands, except per share amounts) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 232,186 $ 246,375 Short-term investments 35,693 27,192 Trade accounts receivable, net of allowances of $ 5,637 and $ 6,917 262,160 272,370 Inventories, net 489,106 429,090 Prepaid expenses 94,111 77,0

View Full Filing

View this 10-Q filing on SEC EDGAR